1. Home
  2. UFCS vs TBPH Comparison

UFCS vs TBPH Comparison

Compare UFCS & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Fire Group Inc.

UFCS

United Fire Group Inc.

N/A

Current Price

$37.15

Market Cap

929.5M

Sector

Finance

ML Signal

N/A

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

N/A

Current Price

$13.94

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UFCS
TBPH
Founded
1946
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
929.5M
1.0B
IPO Year
1995
2013

Fundamental Metrics

Financial Performance
Metric
UFCS
TBPH
Price
$37.15
$13.94
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$40.50
$18.50
AVG Volume (30 Days)
117.8K
773.3K
Earning Date
05-13-2026
06-01-2026
Dividend Yield
2.12%
N/A
EPS Growth
87.45
N/A
EPS
4.48
0.88
Revenue
$1,386,412,000.00
$15,386,000.00
Revenue This Year
$3.00
$70.90
Revenue Next Year
$19.26
N/A
P/E Ratio
$8.42
$15.36
Revenue Growth
10.62
N/A
52 Week Low
$25.01
$7.90
52 Week High
$40.63
$21.03

Technical Indicators

Market Signals
Indicator
UFCS
TBPH
Relative Strength Index (RSI) 46.00 26.40
Support Level $35.64 $13.58
Resistance Level $37.87 $14.76
Average True Range (ATR) 1.04 0.83
MACD -0.22 -0.62
Stochastic Oscillator 20.66 12.76

Price Performance

Historical Comparison
UFCS
TBPH

About UFCS United Fire Group Inc.

United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: